

Pioneering GTPase and Oncogene Product Development since 2010

CTC-BIOPSY®-A10 AUTOANALYZER SYSTEM

CTCBIOPSY® A10 PRODUCT FEATURE

Easy Operation:

- -- High automation, 10 mins to complete CTC capture and enrichment of 5ml of whole blood.
- -- Nano-microscreen technology, no reliance on specific cell marker, suitable for all types of tumors.

Exclusive CTM:

- -- No lysis of red blood cells or pre-centrifugation to preserve the CTM intact, direct observation under a microscope.
- -- Pioneer in accurate classification of CTM in China, screen patients containing neutrophil CTM with the highest risk of metastasis.

Adequate Data:

- -- The first CTC device certified by NMPA in 2015, with international patent.
- -- Over 30,000 clinical samples' validation in over 100 Grade-A tertiary hospitals in China.
- -- Autonomous downstream analyses, such as IF, IHC, FISH and sequencing to meet the requirements of clinical research.

SUPERIOR PERFORMANCE OF CTC-BIOPSY®-A10

Optimized isolation technology by size of epithelial tumor cells (ISET) can accurately and reliably capture



Pioneering GTPase and Oncogene Product Development since 2010

abnormal cells in blood, providing an efficient solution for tumor screening.

AUTOMATED DEVICE
High-precision peristaltic pump with
negative pressure
High-precision pressure sensor
Automatic control and simulation


EASY OPERATION
Friendly operation interface
Sorting of samples with one click
Real-time display of blood sample
processing




AUTHORITATIVE IDENTIFICATION Norms for identification of cell morphology formulated by authoritative pathology experts QUICK SEPARATION
No reliance on cell marker for separation
Single sample isolation time <10 mins

CTC-BIOPSY®-A10 PATENTED ISET TECHNOLOGY

Basic principle: ISET technology uses the size and deformability of tumor cells to achieve separation, then use cell morphology for identification.





With good light transmission, second-generation nano polymer material is resistant to various staining reagents, allowing direct observation of cells in visible light.

Nano-microsieve technology broke the foreign monopoly, high-



Pioneering GTPase and Oncogene Product Development since 2010


precision lithography machine for laser lithography.

13mm micro sieve membrane has 160,000 nano micro sieves with an aperture of 8um to maximize the sorting of blood cells and tumor cell enrichment.

Uniform hole spacing Excellent light transmission of membrane Uniform aperture Resistance to various staining reagents

CTC-BIOPSY®-HIGH DETECTION RATE OF CTM

CTC detection data of the CTC-BIOPSY® system in 2018-2020 showed an average CTC detection rate for each tumor is 80.90%, CTM (Circulating Tumor Microemboli) detection rate is 12.52%, and the ratio of CTM to total CTC detection was consistent with study data from Nature in 2019.



Type	Total cases	Detected Qty	Detection rate	Mean	Median
CTC	9304	7527	80.90%	5.154	3
CTM		1165	12.52%	0.7813	0
CTCs		7686	82.61%	16.42	3

CTC-BIOPSY®-ACCURATE CLASSIFICATION OF CTM

CTC neutrophil clusters, representing a critical weakness in the metastatic process, the link between neutrophils and CTC drives the progress of cell cycle in the blood flow and expands the metastatic potential of CTC.

CTCBIOPSY® is the only NMPA approved detection system in China, it can efficiently capture CTMs containing neutrophils, which can be seen directly with the eye under ordinary optical microscopes. Patients with a higher



Pioneering GTPase and Oncogene Product Development since 2010

and treatment.

CTCBIOPSY® Systematically Detect CTM Containing Neutrophils:

